How to Take Semaglutide for Weight Loss: Peptide Guide

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide for weight loss is administered as a weekly subcutaneous injection or daily oral tablet, with dosing starting at 0.25 mg and titrating to 2.4 mg over 16-30 weeks depending on tolerance. Research shows approximately 15-22% weight loss in clinical trials when combined with lifestyle modification.

Proper semaglutide administration extends beyond injection technique—it involves understanding your baseline metabolic state, recognizing how your body signals satiety, and monitoring early tolerance markers. PlexusDx precision-wellness approach integrates genetic and biomarker context to support more informed conversations with your healthcare provider about optimizing your specific peptide protocol.

Injection Technique and Administration Routes for Semaglutide

Semaglutide injection is administered subcutaneously (under the skin) once weekly in the abdomen, thigh, or upper arm. Proper site rotation minimizes lipohypertrophy—abnormal fat tissue growth at injection sites. Most patients use a prefilled pen or vial with a small needle, requiring minimal training.

Oral semaglutide (tablets) is taken daily on an empty stomach, 30 minutes before food or beverages. Bioavailability is enhanced by fasting state and specific pH conditions in the stomach. Injection and oral routes achieve different pharmacokinetic profiles; your provider determines the best route based on tolerability, adherence capacity, and your clinical context.

Dosing Protocols, Titration Schedules, and Clinical Response Patterns

Semaglutide dosing follows a gradual titration schedule to minimize gastrointestinal side effects. Injection dosing typically starts at 0.25 mg weekly, increasing by 0.25 mg every 4 weeks until reaching the therapeutic dose of 2.4 mg. This 16-30 week ramp allows your system to adapt and helps identify your individual tolerance threshold.

Administration Phase	Typical Dose	Duration	Expected Clinical Signal
Initiation	0.25 mg weekly (injection) or 3 mg daily (oral)	Weeks 1-4	Mild appetite reduction; GI adjustment
Early titration	0.5–1.0 mg weekly (injection) or 7 mg daily (oral)	Weeks 5-12	Increased satiety; potential mild nausea
Mid-phase titration	1.7 mg weekly (injection) or 14 mg daily (oral)	Weeks 13-20	Sustained appetite suppression; GI tolerance improves
Maintenance	2.4 mg weekly (injection) or 14 mg daily (oral)	Ongoing	Stable weight loss; individualized tolerability

Biomarker Indicators That May Inform Semaglutide Response and Optimization

Beyond injection technique, several biomarkers can provide context for predicting semaglutide responsiveness and side effect patterns. Fasting glucose, insulin resistance (HOMA-IR), inflammatory markers (CRP), and GLP-1 receptor sensitivity—indicated by baseline appetite signaling—may help frame your individual treatment trajectory.

Genetic variations in GLP-1 receptor pathways, FTO gene polymorphisms, and MC4R variants can predispose individuals to different weight loss magnitudes and side effect profiles. Understanding these predispositions may help you and your provider set realistic expectations and adjust dosing or formulation strategically.

Safety Considerations, Monitoring, and Who Should Use Semaglutide

Semaglutide is contraindicated in personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, and severe pancreatitis. Common side effects include nausea, vomiting, diarrhea, and constipation—most mild to moderate and transient. Serious but rare adverse events include acute kidney injury, gallbladder issues, and retinopathy changes in diabetic patients.

Semaglutide is appropriate for adults with BMI ≥27 with weight-related conditions or BMI ≥30 without comorbidities, under medical supervision. Your provider should evaluate thyroid function, kidney function, and gastrointestinal history before initiation. Regular follow-up appointments monitor tolerability, efficacy, and any emerging safety signals.

How PlexusDx Supports a More Personalized Approach

The PlexusDx Precision Peptide Genetic Test examines key variants in GLP1R, GIPR, FTO, and MC4R genes that may help provide context for individual semaglutide response patterns. These predispositions may correlate with appetite regulation capacity, metabolic efficiency, and side effect susceptibility. This information should be interpreted with your qualified healthcare provider as part of a comprehensive clinical evaluation.

Your genetic profile in GLP-1 receptor pathways may reveal predispositions toward robust versus modest appetite suppression, and variants in MC4R and FTO may contextualize expected weight loss magnitude ranges. The test does not predict exact medication response or guarantee outcomes—rather, it reveals predispositions in peptide genetic pathways that can support more granular optimization conversations.

Understanding your biomarker and genetic context before starting semaglutide may help you and your provider anticipate dosing strategies, recognize expected tolerability patterns, and set personalized success metrics. PlexusDx compounded semaglutide options—from $179/month—combined with genetic insights can support a more informed, precision-wellness approach to peptide therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $229-$509/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.